AbbVie plans to present data from 38 abstracts of Humira (adalimumab) and other products in the company’s investigational immunology medicine portfolio at the 2017 American College of Rheumatology (ACR)/Association for Rheumatology Health Professionals (ARHP) annual meeting Nov. 3-8, in San Diego.
Patients in Japan with hepatitis C virus (HCV) infection have a new eight-week treatment available now that the Japanese Ministry of Health, Labour and Welfare has approved Maviret (glecaprevir/pibrentasvir), AbbVie said in a release.
AbbVie said a subcommittee of the European Medicines Agency has recommended marketing authorization approval of hepatitis C drug Maviret, a step toward broadening the available treatments for patients with liver and kidney disease in approximately 30 European and Scandinavian countries.
Patients suffering from arthritis may benefit from being part of a patient support group, according to a study conducted by AbbVie Inc., a Chicago-based pharmaceutical company that manufactures the arthritis drug Humira.
AbbVie said the results of an analysis of three Phase III trials evaluating Imbruvica (ibrutinib) in treating chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) were presented at the 17th International Workshop on Chronic Lymphocytic Leukemia (iwCLL) biennial meeting in New York.
AbbVie said 23 abstracts, including data on approved and investigational oncology medicines, have been accepted for presentations at the 53rd annual meeting of the American Society of Clinical Oncology (ASCO) on June 2-6 in Chicago.
A gruesome potential side effect of stem cell or bone marrow transplants in oncology patients may soon meet its match in AbbVie’s Imbruvica, which has been accepted for review by the FDA for chronic graft-versus-host disease.
Global biopharmaceutical company AbbVie has received priority review from the Japanese Ministry of Health, Labour and Welfare for Glecaprevir/Pibrentasvir, its drug for the treatment of chronic hepatitis C.